Amsacrine
- Generic Name
- Amsacrine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O3S
- CAS Number
- 51264-14-3
- Unique Ingredient Identifier
- 00DPD30SOY
- Background
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppressi...
- Indication
For treatment of acute myeloid leukaemia.
- Associated Conditions
- Refractory Leukemia
- Associated Therapies
- -
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 38
- Registration Number
- NCT05807932
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇩🇪Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany
🇩🇪Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 142
- Registration Number
- NCT03765541
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷CHU de Limoges, Limoges, France
🇫🇷CHU de Bordeaux, Pessac, France
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)
- Conditions
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 160
- Registration Number
- NCT01324063
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
- Conditions
- Interventions
- Drug: AmsacrineDrug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: DexamethasoneDrug: Daunorubicin hydrochlorideDrug: Doxorubicin hydrochlorideDrug: Etoposide phosphateDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine sulfateRadiation: Whole-brain radiation therapy
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 745
- Registration Number
- NCT01228331
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
🇩🇪University Medical Center Hamburg - Eppendorf, Hamburg, Germany
🇩🇪Johannes Gutenberg University, Mainz, Germany
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 135
- Registration Number
- NCT00840684
- Locations
- 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 500
- Registration Number
- NCT00002719
- Locations
- 🇮🇹
Azienda Policlinico Umberto Primo, Rome, Italy
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-30
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00003436
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00002658
- Locations
- 🇬🇧
University of Wales College of Medicine, Cardiff, Wales, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.